Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 5, 2009
Wed, February 4, 2009 Curis to Present at the 11th Annual BIO CEO Investor Conference
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 11th Annual BIO CEO Investor Conference, at 11:00 a.m. EST on February 10, 2009, at the Waldorf Astoria Hotel in New York, New York.
Dan Passeri, Curis' President and Chief Executive Officer, will provide an overview of the status of GDC-0449, an orally-administered small molecule inhibitor of the Hedgehog pathway that is currently in Phase II clinical testing under collaboration with Genentech. Mr. Passeri also will discuss CUDC-101, CUDC-305 and Curis' other targeted cancer programs, in addition to other corporate activities.
There will also be a corresponding webcast of the panel discussion, which can be accessed by visiting:
[ http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=CRIS&item_id=2079490 ]
The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will also be available for 30 days on the Investor Relations section of the Curis website at [ www.curis.com ].
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at [ www.curis.com ].
